







**Figure S1.** Shallow whole-genome plasma sequencing profiles before initiation of osimertinib and at the time of progression to osimertinib. TF Tumor fraction







Case 5 - Pre-osimertinib. TF: 5.0%




Case 5 - Resistance. TF: 3.9%







Case 6 - Pre-osimertinib. TF: 4.1%




Case 6 - Resistance. TF: 3.9%







Case 9 - Pre-osimertinib. TF: 1.0%




Case 9 - Resistance. TF: 3.4%




Case 10 - Pre-osimertinib. TF: 19.4%




Case 10 - Resistance. TF: 3.4%




Case 11 - Pre-osimertinib. TF: 22.5%




Case 11 - Resistance. TF: 6.7%




Case 12 - Pre-osimertinib. TF: 5.6%




Case 12 - Resistance. TF: 5.9%




Case 13 - Pre-osimertinib. TF: 5.3%




Case 13 - Resistance. TF: 10.2%




Case 14 - Pre-osimertinib. TF: 4.0%




Case 14 - Resistance. TF: 3.3%




Case 15 - Pre-osimertinib. TF: 3.1%




Case 15 - Resistance. TF: 3.3%



Case 16 - Pre-osimertinib. TF: 42.4%




Case 16 - Resistance. TF: 23.7%







Case 17 - Pre-osimertinib. TF: 4.8%




Case 17 - Resistance. TF: 4.1%







Case 18 - Pre-osimertinib. TF: 4.9%




Case 18 - Resistance. TF: 4.8%







Case 21 - Pre-osimertinib. TF: 5.1%




Case 21 - Resistance. TF: 4.9%







Case 22 - Pre-osimertinib. TF: 3.7%




Case 22 - Resistance. TF: 3.2%







Case 25 - Pre-osimertinib. TF: 1.6%




Case 25 - Resistance. TF: 15.5%







Case 26 - Pre-osimertinib. TF: 23.8%




Case 26 - Resistance. TF: 42.6%







Case 29 - Pre-osimertinib. TF: 14.6%




Case 29 - Resistance. TF: 5.3%







Case 30 - Pre-osimertinib. TF: 6.9%




Case 30 - Resistance. TF: 30.8%









Case 33 - Pre-osimertinib. TF: 6.2%




Case 33 - Resistance. TF: 4.3%




Case 34 - Pre-osimertinib. TF: 3.9%




Case 34 - Resistance. TF: 4.0%




Case 35 - Pre-osimertinib. TF: 5.7%




Case 35 - Resistance. TF: 4.2%




Case 36 - Pre-osimertinib. TF: 5.9%




Case 36 - Resistance. TF: 4.0%




Case 37 - Pre-osimertinib. TF: 3.9%




Case 37 - Resistance. TF: 7.8%




Case 38 - Pre-osimertinib. TF: 5.1%




Case 38 - Resistance. TF: 1.8%




Case 39 - Pre-osimertinib. TF: 3.8%




Case 39 - Resistance. TF: 2.9%




Case 40 - Pre-osimertinib. TF: 7.9%




Case 40 - Resistance. TF: 4.5%




Case 41 - Pre-osimertinib. TF: 4.1%




Case 41 - Resistance. TF: 4.5%




Case 42 - Pre-osimertinib. TF: 2.1%



Case 42 - Resistance. TF: 8.3%



Case 43 - Pre-osimertinib. TF: 5.1%



Case 43 - Resistance. TF: 5.0%

